Gubra
  • Services
    • CRO NASH
    • CRO CKD
    • CRO CVD
    • CRO obesity
    • CRO Diabetes
    • CRO customized services
  • Discovery
    • Target Discovery
    • Drug Discovery
    • StreaMLine
  • Capabilities
    • In vivo pharmacology
    • Histology & Stereology
    • Imaging
    • NGS & Bioinformatics
    • Ex vivo assays
    • Molecular pharmacology
    • Peptide chemistry
    • Gubra video gallery
  • Publications
  • Careers
  • About us
    • Company
    • Leadership
    • Events
    • Webinars
    • News
    • Corporate Social Responsibility
    • CSR Activities
Select Page

Gubra announces research collaboration agreement with Sanofi to discover and develop peptide-based drugs targeting diabetes and obesity

Press Release Hørsholm, September 23, 2013 Gubra today announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment...

Recent Posts

  • Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
  • Gubra wins EY Entrepreneur of the Year, Region Zealand 2020
  • Gubra chooses sustainable pension scheme
  • A call for simple and comparable CSR reporting
  • A year of solid financial growth, scientific breakthroughs, and strong green commitment

Recent Comments

    Archives

    • March 2021
    • December 2020
    • June 2020
    • May 2020
    • March 2020
    • October 2019
    • June 2019
    • May 2019
    • June 2018
    • September 2017
    • August 2017
    • June 2016
    • September 2013

    Categories

    • News
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Company
    • Careers
    • CSR
    • Contact
    • Privacy policy
    © 2021 Gubra
    We use cookies to ensure that we give you the best experience on our website. Please accept usage of cookies before continuing.AcceptNoRead our policy